EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency

Susana Gómez-Ramírez, Elisa Brilli, Germano Tarantino, Domenico Girelli iD, Manuel Muñoz iD

Pharmaceuticals · 06.06.2023 · 16 (6) · 847

DOI: 10.3390/ph16060847 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 06.06.2023. Verfasst von Susana Gómez-Ramírez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University Hospital "Virgen de la Victoria", 29010 Málaga, Spain. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iron deficiency (ID) and iron deficiency anemia (IDA) are highly prevalent worldwide. Oral iron salts, especially ferrous sulfate, are commonly used for the treatment of iron deficiency (ID). However, its use is associated with gastrointestinal side effects, thus compromising treatment compliance. Intravenous iron administration is a more costly and logistically complex alternative and is not risk-free, as infusion and hypersensitivity reactions may occur. Sucrosomial® iron is an oral formulation consisting of ferric pyrophosphate conveyed by a phospholipid and sucrester matrix (sucrosome®). Intestinal Sucrosomial® iron absorption is mediated by enterocytes and M cells, through the paracellular and transcellular routes, and occurs mostly as intact particles. These pharmacokinetic properties of Sucrosomial® iron result in higher iron intestinal absorption and excellent gastrointestinal tolerance compared to oral iron salts. The evidence derived from clinical studies supports the use of Sucrosomial® iron as a valid first option for the treatment of ID and IDA, especially for subjects who are intolerant or refractory to conventional iron salts. Newer evidence also demonstrates the effectiveness of Sucrosomial® iron, with a lower cost and fewer side effects, in certain conditions usually treated with IV iron in current clinical practice.

Schlagwörter

Stichwörter der Autor:innen

Sucrosomial® ironanemiabioavailabilityefficacyintravenous ironiron deficiencyoral iron saltspatient blood managementtolerability

Autor:innen und Institutionen

  • Department of Internal Medicine, University Hospital "Virgen de la Victoria", 29010 Málaga, Spain.
  • Scientific Department, Alesco S.r.l., Via delle Lenze, 56122 Pisa, Italy.
  • Scientific Department, Pharmanutra S.p.A., Via delle Lenze, 56122 Pisa, Italy.
  • Department of Medicine, University of Verona, 37129 Verona, Italy.
  • Perioperative Transfusion Medicine, Department of Surgical Specialties, Biochemistry and Immunology, School of Medicine, Campus de Teatinos, 29071 Málaga, Spain.

ORCID-Profile: Domenico Girelli, Manuel Muñoz

Zitieren

APA

Gómez-Ramírez, S., Brilli, E., Tarantino, G., Girelli, D., & Muñoz, M. (2023). Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency. Pharmaceuticals, 16(6), 847. https://doi.org/10.3390/ph16060847

Vancouver

Gómez-Ramírez S, Brilli E, Tarantino G, Girelli D, Muñoz M. Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency. Pharmaceuticals. 2023;16(6):847. doi:10.3390/ph16060847

BibTeX
@article{GmezRamrez2023,
  author = {Gómez-Ramírez, Susana and Brilli, Elisa and Tarantino, Germano and Girelli, Domenico and Muñoz, Manuel},
  title = {Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {6},
  pages = {847},
  doi = {10.3390/ph16060847}
}
Kostenlos starten →